Get Ready for the GLP-1 Debate in Sports
Newser • • sports
Key Points:
- Serena Williams' tennis comeback was cut short due to her doubles partner's knee injury, but she plans to compete again in Germany next week.
- Williams is a high-profile athlete using the GLP-1 weight-loss drug Zepbound, which she started post-pregnancy to address biological challenges with weight loss.
- GLP-1 drugs like semaglutide and tirzepatide are not banned by the World Anti-Doping Agency (WADA) but are under monitoring as potential performance enhancers.
- The debate centers on whether these drugs violate the "spirit of sport," especially if used as a substitute for training, with concerns heightened by evolving drug formulations that may reduce side effects.
- Williams' public use of GLP-1 medication could accelerate discussions within sports and anti-doping authorities about the regulation and ethics of modern weight-loss drugs.